Compare McCormick & Company, Incorporated (MKC) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Tempus AI — how do they compare? McCormick & Company, Incorporated trades at $51.5 (market cap $13.90B), while Tempus AI trades at $60.4 (market cap $11.13B). The key difference: McCormick & Company, Incorporated is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 3.73% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| MKC | TEM | |
|---|---|---|
Market Cap | $13.90B | $11.13B |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $71.65 | $103.25 |
52-Week Low | $45.60 | $41.55 |
Enterprise Value | $18.50B | $11.75B |
Dividend Yield | 3.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $51.90, down 0.35% with a bearish technical signal. The stock shows strong fundamentals with a low P/E of 8.64, robust 21.91% net margin, and consistent revenue growth to $6.84B in 2025. Recent Q1 2026 earnings beat expectations, while analyst consensus is mixed with 36.67% buy ratings. The pending Unilever merger and upcoming Q3 2026 earnings on October 1, 2026, are key catalysts.
MKC presents a value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term pressure. The Unilever deal integration and margin expansion potential support long-term growth, but execution risks and competitive pressures remain concerns. Current price sits near the analyst low target of $52.00, offering limited downside protection.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company reported a net loss of $245.03M in 2025 despite revenue of $1.27B, but recent quarterly EPS beats and FDA clearance for an AI-enabled ECG product (Business Wire, 2026-08-24) highlight growth potential in precision medicine. Analyst consensus is strongly bullish with a $69.20 price target.
Outlook: TEM's AI-driven healthcare platform positions it for long-term growth amid industry shifts toward personalized medicine, though persistent losses and high P/B of 25.01 pose valuation risks. Near-term catalysts include continued execution on recent contracts and pipeline developments, but investors face volatility from cash burn and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
